» Articles » PMID: 38744846

Mitochondrial Dysfunction: Mechanisms and Advances in Therapy

Overview
Date 2024 May 14
PMID 38744846
Authors
Affiliations
Soon will be listed here.
Abstract

Mitochondria, with their intricate networks of functions and information processing, are pivotal in both health regulation and disease progression. Particularly, mitochondrial dysfunctions are identified in many common pathologies, including cardiovascular diseases, neurodegeneration, metabolic syndrome, and cancer. However, the multifaceted nature and elusive phenotypic threshold of mitochondrial dysfunction complicate our understanding of their contributions to diseases. Nonetheless, these complexities do not prevent mitochondria from being among the most important therapeutic targets. In recent years, strategies targeting mitochondrial dysfunction have continuously emerged and transitioned to clinical trials. Advanced intervention such as using healthy mitochondria to replenish or replace damaged mitochondria, has shown promise in preclinical trials of various diseases. Mitochondrial components, including mtDNA, mitochondria-located microRNA, and associated proteins can be potential therapeutic agents to augment mitochondrial function in immunometabolic diseases and tissue injuries. Here, we review current knowledge of mitochondrial pathophysiology in concrete examples of common diseases. We also summarize current strategies to treat mitochondrial dysfunction from the perspective of dietary supplements and targeted therapies, as well as the clinical translational situation of related pharmacology agents. Finally, this review discusses the innovations and potential applications of mitochondrial transplantation as an advanced and promising treatment.

Citing Articles

Insulin resistance and cancer: molecular links and clinical perspectives.

Caturano A, Erul E, Nilo R, Nilo D, Russo V, Rinaldi L Mol Cell Biochem. 2025; .

PMID: 40089612 DOI: 10.1007/s11010-025-05245-8.


SLC5A3 depletion promotes apoptosis by inducing mitochondrial dysfunction and mitophagy in gemcitabine-resistant pancreatic cancer cells.

Kim M, Hong W, Kang H, Kim J, Lee D, Cheong J Cell Death Dis. 2025; 16(1):161.

PMID: 40055335 PMC: 11889219. DOI: 10.1038/s41419-025-07476-5.


Important regulatory role of mitophagy in diabetic microvascular complications.

Hu X, Lv J, Zhao Y, Li X, Qi W, Wang X J Transl Med. 2025; 23(1):269.

PMID: 40038741 PMC: 11877814. DOI: 10.1186/s12967-025-06307-7.


The critical role of mitochondrial dysfunction in ADT-induced neurotoxicity.

Lin Y, Lin K, Shao I Prostate Cancer Prostatic Dis. 2025; .

PMID: 40032984 DOI: 10.1038/s41391-025-00958-9.


Engineered mitochondria in diseases: mechanisms, strategies, and applications.

Li M, Wu L, Si H, Wu Y, Liu Y, Zeng Y Signal Transduct Target Ther. 2025; 10(1):71.

PMID: 40025039 PMC: 11873319. DOI: 10.1038/s41392-024-02081-y.


References
1.
Cadenas S . ROS and redox signaling in myocardial ischemia-reperfusion injury and cardioprotection. Free Radic Biol Med. 2018; 117:76-89. DOI: 10.1016/j.freeradbiomed.2018.01.024. View

2.
Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

3.
Schriner S, Linford N, Martin G, Treuting P, Ogburn C, Emond M . Extension of murine life span by overexpression of catalase targeted to mitochondria. Science. 2005; 308(5730):1909-11. DOI: 10.1126/science.1106653. View

4.
Graham D, Huynh N, Hamilton C, Beattie E, Smith R, Cocheme H . Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension. 2009; 54(2):322-8. DOI: 10.1161/HYPERTENSIONAHA.109.130351. View

5.
Kim H, Choi W, Sorscher N, Park H, Tronche F, Palmiter R . Genetic reduction of mitochondrial complex I function does not lead to loss of dopamine neurons in vivo. Neurobiol Aging. 2015; 36(9):2617-27. PMC: 4523431. DOI: 10.1016/j.neurobiolaging.2015.05.008. View